Research and Markets: Recordati Is Active In the Following Areas of Research: Cardiovascular; Central Nervous System, Gastroenterology/Urology and Anti-Infectives - Recordati: Prospects to 2010.DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c47475) has announced the addition of Recordati: Prospects to 2010 from Espicom Business Intelligence Introduction Espicom Business Intelligence is a publisher of independent and impartial information and analysis services focusing on the pharmaceutical and medical device markets. to their offering. Pharmaceutical company intelligence reports provide a full review of the company's activities together with five-year sales forecasts Sales forecast A key input to a firm's financial planning process. External sales forecasts are based on historical experience, statistical analysis, and consideration of various macroeconomic factors. for its key products. The company's financial performance is covered in-depth, from its latest results to a complete analysis of its latest full fiscal year and an outlook for the future. A section on company strategy covers mergers, acquisitions and divestitures, key agreements, products and R&D. An overview of key products and R&D is followed by a comprehensive review of the company's product portfolio and research and development pipeline by therapeutic area. In addition, supplementary appendices ap·pen·di·ces n. A plural of appendix. provide more in-depth information on financials, agreements and corporate events. Recordati is active in the following areas of research: Cardiovascular; Central Nervous System, Gastroenterology/Urology and Anti-infectives. However, future research efforts will focus on fixed combinations in the treatment of hypertension and the development of therapies for micturition micturition /mic·tu·ri·tion/ (mik?tu-ri´shun) urination. mic·tu·ri·tion n. 1. See urination. 2. The desire to urinate. 3. The frequency of urination. disorders. This report provides a full review of the company's activities together with sales forecasts for key products to 2010. Recordati was established in 1926 in Milan, Italy and is now listed on the Italian Stock Exchange Italian Stock Exchange (ISE) The Milan-based stock exchange, which came into effect after the unification of Italy's ten national exchanges in 1991. All listed securities are traded electronically. . The company employs more than 1,900 people and its products are sold in about 100 countries. Recordati is active in the following areas of research: Cardiovascular; Central Nervous System, Gastroenterology/Urology and Anti-infectives. However, future research efforts will focus on fixed combinations in the treatment of hypertension and the development of therapies for micturition disorders. Current Growth Drivers Zanidip (lercanidipine), an in-house developed calcium channel blocker calcium channel blocker n. Any of a class of drugs that inhibit movement of calcium ions across a cell membrane, used in the treatment of cardiovascular disorders. , is Recordati's top selling product by a considerable margin, accounting for around 15 per cent of the company's total revenue. The product continues to sell well, and Recordati is investing in new combinations and formulations which should ensure future success and growth. Peptazol (pantoprazole), a proton pump inhibitor proton pump inhibitor n. A class of drugs that inhibit gastric acid secretion by interfering with the movement of hydrogen ions across cell membranes and are used mainly to treat peptic ulcers, gastroesophageal reflux disease, and esophagitis. for the treatment of ulcers and gastro-oesophageal reflux disease, has demonstrated good year-on-year growth since its 2002 launch in the Italian market. Key Late-Phase Products Reaching the Market Place Zanitek (lercanidipine+enalapril) is a new fixed combination treatment for hypertension developed by Recordati. In July 2006, it was approved in Germany, which will act as the reference member state for approval in the rest of Europe. Its launch will support the sales of Zanidip and aid Recordati in making further gains in the European hypertension market. Fentanyl fentanyl /fen·ta·nyl/ (fen´tah-nil) an opioid analgesic; the citrate salt is used as an adjunct to anesthesia, in the induction and maintenance of anesthesia, in combination with droperidol (or similar agent) as a neuroleptanalgesic, and is a centrally acting, potent analgesic analgesic (ăn'əljē`zĭk), any of a diverse group of drugs used to relieve pain. Analgesic drugs include the nonsteroidal anti-inflammatory drugs (NSAIDs) such as the salicylates, narcotic drugs such as morphine, and synthetic drugs which is being developed as a transdermal patch transdermal patch: see skin patch. for the treatment of moderate to severe pin. Recordati has acquired rights to market this product in all the major European markets and the company hopes its launch will expand its analgesic product portfolio. Content Outline: Principal Operating Results Latest Results EXECUTIVE SUMMARY PRODUCT PORTFOLIO / RESEARCH & DEVELOPMENT APPENDIX 1 - FINANCIAL PERFORMANCE APPENDIX 2 - KEY AGREEMENTS APPENDIX 3 - INFRASTRUCTURE APPENDIX 4 - KEY PHARMACEUTICAL SUBSIDIARIES / JOINT VENTURES APPENDIX 5 - PRODUCT INDEX Index of Tables For more information visit http://www.researchandmarkets.com/reports/c47475 |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion